Citi Pharma Limited (PSX:CPHL)

Citi Pharma Balance Sheet

Financials in millions PKR. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Cash & Equivalents	23.15	603.55	87.9	54.61	27.48	3,074
Short-Term Investments	892.35	919.59	1,222	1,393	1,660	-
Trading Asset Securities	-	66.5	108.81	132.36	312.12	-
Cash & Short-Term Investments	915.49	1,590	1,418	1,580	2,000	3,074
Cash Growth	-30.74%	12.08%	-10.26%	-20.97%	-34.96%	3337.25%
Accounts Receivable	3,401	3,078	2,197	1,882	1,402	444.55
Other Receivables	-	150.02	203.26	96.29	45.77	-
Receivables	3,401	3,228	2,400	1,978	1,447	444.55
Inventory	3,795	3,930	3,203	2,609	1,692	778.19
Other Current Assets	795.64	723.98	613.03	415.98	458.15	204.08
Total Current Assets	8,908	9,472	7,635	6,584	5,597	4,501
Property, Plant & Equipment	8,679	8,688	3,530	3,122	2,258	1,735
Long-Term Accounts Receivable	-	-	-	23.65	-	8.61
Other Long-Term Assets	279.98	279.98	274.76	254.54	272.06	254.54
Total Assets	17,867	18,439	11,439	9,984	8,127	6,499
Accounts Payable	3,618	3,479	3,374	1,938	1,618	993.58
Accrued Expenses	66.98	236.33	216.54	206.62	149.67	58.54
Short-Term Debt	2,732	2,869	1,437	1,768	521.57	12.2
Current Portion of Long-Term Debt	-	-	12.86	55.88	160.69	108.71
Current Portion of Leases	13.91	15.8	5.42	5.67	4.77	2.99
Current Income Taxes Payable	99.73	519.68	470.83	393.19	404.18	126.87
Current Unearned Revenue	-	-	0.58	3.04	14.51	5.86
Other Current Liabilities	4.07	185.89	83.03	82.1	137.28	526.77
Total Current Liabilities	6,535	7,305	5,599	4,453	3,010	1,836
Long-Term Debt	-	-	-	8.54	250.17	189.16
Long-Term Leases	59.9	64.86	-	4.37	6.27	7.76
Long-Term Unearned Revenue	-	-	-	0.58	32.17	9.27
Pension & Post-Retirement Benefits	-	99.7	82.62	50.34	31.94	14.25
Long-Term Deferred Tax Liabilities	-	102.07	124.09	94.24	82.3	77.17
Other Long-Term Liabilities	200.62	0	-	-	-	-0
Total Liabilities	6,796	7,572	5,806	4,611	3,413	2,133
Common Stock	2,285	2,285	2,285	2,285	2,285	1,350
Additional Paid-In Capital	1,392	1,392	1,392	1,392	1,392	-
Retained Earnings	2,011	1,807	1,648	1,388	728.54	380.61
Comprehensive Income & Other	5,385	5,385	309.29	309.29	309.29	2,635
Shareholders' Equity	11,071	10,868	5,633	5,373	4,714	4,366
Total Liabilities & Equity	17,867	18,439	11,439	9,984	8,127	6,499
Total Debt	2,806	2,950	1,455	1,843	943.48	320.81
Net Cash (Debt)	-1,891	-1,360	-36.55	-262.2	1,056	2,754
Net Cash Growth	-	-	-	-	-61.65%	-
Net Cash Per Share	-8.28	-5.95	-0.16	-1.15	4.66	14.77
Filing Date Shares Outstanding	228.46	228.46	228.46	228.46	228.46	148.5
Total Common Shares Outstanding	228.46	228.46	228.46	228.46	228.46	148.5
Working Capital	2,373	2,166	2,035	2,131	2,586	2,666
Book Value Per Share	48.46	47.57	24.66	23.52	20.63	29.40
Tangible Book Value	11,071	10,868	5,633	5,373	4,714	4,366
Tangible Book Value Per Share	48.46	47.57	24.66	23.52	20.63	29.40
Land	-	6,940	1,865	1,865	1,421	1,049
Buildings	-	673.95	661.56	485.03	309.33	214.96
Machinery	-	1,758	1,525	1,194	915.01	795.57
Construction In Progress	-	49.11	130.04	70.39	14.33	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.